

June 7, 2024

VIA EDGAR AND FACSIMILE

United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard

Re: Lexaria Bioscience Corp. (the "**Company**")
Registration Statement on Form S-1
File No. 333-279909

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30PM EDT on Tuesday, June 11, 2024, or as soon thereafter as is practicable.

If you have any questions, please call Avital Perlman at 212-930-9700.

Very truly yours,

LEXARIA BIOSCIENCE CORP.

By: /s/ Christopher Bunka

Name: Christopher Bunka

Title: Chief Executive Officer